Osteoporosis Therapy: RANK-ligand Inhibitors

Question 1

RANKL inhibitor drug

Answer 1

Denosumab

Question 2

Denosumab MoA

Answer 2

Inhibits RANKL/RANK interaction which inhibits osteoclast activity

Question 3

Denosumab dosing

Answer 3

60mg SQ q6months administered by a HCP

Question 4

Denosumab ADEs

Answer 4

Musculoskeletal pain, dermatologic reactions, hypocalcemia (treat before starting therapy!)

Rare: serious infections, ONJ, atypical fractures

Question 5

Denosumab pearls

Answer 5

1st-line agent

Bone loss is rapid following D/C- consider starting other agents after D/C’ing

Question 6

Is denosumab an antiresorptive or anabolic agent?

Answer 6

Antiresorptive